3-(2-6-dichloro-3-5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea and Urethral-Neoplasms

3-(2-6-dichloro-3-5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea has been researched along with Urethral-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for 3-(2-6-dichloro-3-5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea and Urethral-Neoplasms

ArticleYear
BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
    International journal of molecular sciences, 2018, Oct-15, Volume: 19, Issue:10

    Paclitaxel (PTX) is commonly used to treat urothelial carcinoma (UC) after platinum-based chemotherapy has failed. However, single-agent taxane therapy is not sufficient to inhibit tumor progression and drug resistance in advanced UC. Epithelial-to-mesenchymal transition (EMT) induced by fibroblast growth factor receptor (

    Topics: Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Expression; Gene Expression Profiling; Humans; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Transcriptome; Urethral Neoplasms

2018